Traditional Chinese medicine for preventing and treating acute lung injury

Abstract

The traditional Chinese medicine for preventing and treating the acute lung injury is prepared from the following raw materials in percentage by weight: 24 to 26 percent of radix puerariae, 18 to 22 percent of radix scutellariae, 18 to 22 percent of rhizoma dioscoreae, 14 to 16 percent of Chinese hibiscus root, 9 to 12 percent of herba kyllingae and 9 to 12 percent of fructus phyllostachys glaucae. The raw materials are rich and easy to obtain, the component compatibility is reasonable, the compound extract of the QFFYT is extracted through a water extraction-alcohol precipitation method, the extraction efficiency and bioavailability of effective components of the QFFYT are improved, a theoretical basis and an experimental basis are provided for application of traditional Chinese medicine in inflammatory diseases such as acute lung injury, and the social and economic benefits are remarkable.

Description

Technical Field

[0001] The present invention relates to the field of medicine, in particular to a traditional Chinese medicine for preventing and treating acute lung injury. Background Art

[0002] Acute lung injury (ALI) is a severe clinical syndrome caused by a variety of factors, typically accompanied by symptoms such as pulmonary edema, dyspnea, and hypoxemia. If not promptly and effectively treated, it can progress to acute respiratory distress syndrome (ARDS), posing a serious threat to the patient's life. The ICU mortality rate for ARDS patients is as high as 40%, particularly among the elderly and those with underlying medical conditions. Therefore, effective intervention and treatment for ALI are extremely urgent. Despite advances in modern medicine in respiratory support, anti-infective therapy, and hormonal intervention, the current treatment of ALI lacks specific medications. Treatment options primarily rely on supportive care and glucocorticoids, such as dexamethasone. While these medications can effectively suppress inflammatory responses in the short term, long-term or high-dose use can trigger a range of adverse reactions, including immune suppression, increased risk of infection, and endocrine disruption. This severely limits their widespread and sustainable clinical application. This has led to the search for highly effective, low-toxic natural remedies, a key research focus. Traditional Chinese medicine offers the advantages of minimal side effects and diverse mechanisms of action.

[0003] Traditional Chinese medicine theory classifies ALI as a "lung heat syndrome" or "asthma syndrome," and emphasizes regulating the body's balance through methods such as clearing away heat and detoxifying, purging the bowels and purging heat, and promoting blood circulation and removing blood stasis. Although Chinese medicine has natural advantages in regulating multi-system pathological processes, traditional Chinese medicine generally has problems such as insufficient release of active ingredients, low bioavailability, and slow onset of action in actual application, especially the lack of standardized preparations. In addition, the specific mechanism of action, target pathways, and tissue protective effects of Chinese medicine in intervening in acute lung injury are still unclear, and lack systematic research support. Therefore, there is an urgent need to develop a Chinese medicine for the prevention and treatment of acute lung injury to meet the demand. Summary of the Invention

[0004] In view of the above situation, in order to overcome the defects of the existing technology, the purpose of the present invention is to provide a traditional Chinese medicine for preventing and treating acute lung injury, which can effectively solve the problem that Western medicine has large side effects but the current traditional Chinese medicine has poor effects.

[0005] To achieve the above object, the technical solution provided by the present invention is a traditional Chinese medicine for preventing and treating acute lung injury, comprising the following raw materials in percentage by weight: 24-26% of Pueraria root, 18-22% of Scutellaria baicalensis, 18-22% of Dioscorea batatas, 14-16% of Hibiscus sinensis root, 9-12% of Scolopendra subspinipes, and 9-12% of Aralia scabra; wherein the raw materials are crushed and mixed, and water is added to the mixture in a volume ratio of 1:10 to the total weight of the raw materials, and the mixture is boiled, the temperature is maintained at 80-90°C, and the mixture is boiled for 2 hours, the decoction liquid is filtered, the residue is removed, and the original juice is obtained, and the original juice is added. The concentrate is concentrated to a total weight volume ratio of the crude drug of 1:2 (i.e., each milliliter is equivalent to 2.0 grams of the crude drug) to obtain a concentrate, and 70% ethanol in an amount of 2 times the volume of the concentrate is added to the concentrate. The mixture is stirred evenly and allowed to settle for 24 hours. The precipitate is filtered and the supernatant of the concentrate is pre-frozen at -40°C, and then sublimated and dried at -30°C under a vacuum condition of ≤10Pa, and then dried at 30°C until a dry powder extract of the traditional Chinese medicine with a water content of less than 3% is obtained. The weight-to-volume ratio is in g for solids and ml for liquids.

[0006] The raw materials of the invention are abundant and easily available, and the composition is reasonable. The compound extract of Qingfei Fuyuan Decoction (QFFYT) is extracted by a water extraction-alcohol precipitation method, thereby improving the extraction efficiency and bioavailability of its effective ingredients, providing a theoretical basis and experimental foundation for the application of traditional Chinese medicine in inflammatory diseases such as acute lung injury, and having significant social and economic benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 Graph showing the effects of the embodiments of the present invention on lung pathological changes and damage in ALI mice.

[0008] Figure 2 Graph showing the effects of the embodiments of the present invention on the lung index and lung wet / dry ratio in ALI mice.

[0009] Figure 3 Graph showing the effects of the embodiments of the present invention on TNF-α, IL-1β, IL-6, and IL-8 in the bronchoalveolar lavage fluid of ALI mice.

[0010] Figure 4 Graph showing the effect of the embodiments of the present invention on the number of inflammatory cells in the alveolar lavage fluid of ALI mice.

[0011] Figure 5 Graph showing the effects of the embodiments of the present invention on the levels of SOD, MDA, and GSH in the lung tissues of ALI mice.

[0012] Figure 6 Graph showing the effects of the embodiments of the present invention on the expression of TNF-α, IL-1β, IL-6, IL-8, and MCP-1 mRNA in the lung tissue of ALI mice.

[0013] Figure 7Graph showing the effects of the embodiments of the present invention on the expression of p-NF-κB / NF-κB and p-STAT3 / STAT3 proteins in the lung tissue of ALI mice.

[0014] Figure 8 Graph showing the effect of an embodiment of the present invention on the changes in mitochondrial structure in the lung tissue of ALI mice. DETAILED DESCRIPTION

[0015] The following is a detailed description of the present invention with reference to the embodiments and specific implementation methods.

[0016] The present invention is specifically implemented by the following examples.

[0017] Example 1

[0018] A traditional Chinese medicine for preventing and treating acute lung injury comprises the following raw materials in percentage by weight: 25% kudzu root, 20% scutellaria baicalensis, 20% yam, 15% hibiscus root, 10% water centipede and 10% arbutus fructus; wherein the raw materials are crushed and mixed, added with water in a ratio of 1:10 by volume of the total weight of the raw materials, and decocted; after boiling, the temperature is maintained at 80-90°C and decocted for 2 hours; the decocted liquid is filtered, and the medicinal residue is removed to obtain original juice; the original juice is concentrated to a ratio of 1:2 by volume of the total weight of the raw materials to obtain a concentrated solution; 70% ethanol in an amount twice the volume of the concentrated solution is added to the concentrated solution, the solution is stirred evenly, and the solution is allowed to settle for 24 hours; the precipitate is filtered, the supernatant of the concentrated solution is pre-frozen at -40°C, and then sublimated and dried at -30°C under a vacuum condition of ≤10Pa, and then decomposed and dried at 30°C until a dry powder extract of the traditional Chinese medicine with a water content of less than 3% is obtained.

[0019] Example 2

[0020] A traditional Chinese medicine for preventing and treating acute lung injury comprises the following raw materials in percentage by weight: 24% of kudzu root, 22% of scutellaria baicalensis, 18% of yam, 15% of hibiscus root, 12% of water centipede and 9% of black bubble fruit.

[0021] Example 3

[0022] A traditional Chinese medicine for preventing and treating acute lung injury comprises the following raw materials in percentage by weight: 26% of kudzu root, 18% of scutellaria baicalensis, 21% of yam, 14% of hibiscus root, 9% of water centipede and 12% of black bubble fruit.

[0023] Example 4

[0024] A traditional Chinese medicine for preventing and treating acute lung injury comprises the following raw materials in percentage by weight: 26% of kudzu root, 19% of scutellaria baicalensis, 21% of yam, 14% of hibiscus root, 11% of water centipede and 9% of black bubble fruit.

[0025] Example 5

[0026] A traditional Chinese medicine for preventing and treating acute lung injury comprises the following raw materials in percentage by weight: 25% of kudzu root, 21% of scutellaria baicalensis, 19% of yam, 14% of hibiscus root, 10% of water centipede and 11% of black bubble fruit.

[0027] Among the above drugs,

[0028] Pueraria root: Sweet and pungent in flavor, with a cooling nature. It enters the spleen, stomach, and lung meridians. It promotes yang and relieves diarrhea, promotes blood circulation, and detoxifies alcohol. As a pungent and cooling antipyretic, it clears heat, promotes fluid production, and quenches thirst. Pharmacological studies have shown it to combat oxidative stress, reduce the accumulation of inflammatory factors, enhance insulin sensitivity, and reduce insulin resistance. It is commonly used for exogenous fever, headache, stiff neck and back pain, thirst, polydipsia, measles, dysentery, diarrhea, dizziness and headache, hemiplegia caused by stroke, chest pain, and alcohol toxicity.

[0029] Pueraria root: Sweet and pungent in flavor, with a cooling nature. It enters the spleen, stomach, and lung meridians. It promotes yang and relieves diarrhea, promotes blood circulation, and detoxifies alcohol. As a pungent and cooling antipyretic, it clears heat, promotes fluid production, and quenches thirst. Pharmacological studies have shown it to combat oxidative stress, reduce the accumulation of inflammatory factors, enhance insulin sensitivity, and reduce insulin resistance. It is commonly used for exogenous fever, headache, stiff neck and back pain, thirst, polydipsia, measles, dysentery, diarrhea, dizziness and headache, hemiplegia caused by stroke, chest pain, and alcohol toxicity.

[0030] Chinese Yam: Sweet in flavor, neutral in nature. It enters the spleen, lung, and kidney meridians. It strengthens the spleen, tonifies the lungs, strengthens the kidneys, and improves essence. It treats diarrhea due to spleen deficiency, chronic dysentery, consumptive cough, polydipsia, spermatorrhea, leucorrhea, and frequent urination. It nourishes the spleen and stomach, promotes fluid production and benefits the lungs, and tonifies the kidneys and astringes essence. It is used for spleen deficiency, poor appetite, chronic diarrhea, wheezing and coughing due to lung deficiency, spermatorrhea, leucorrhea, frequent urination, and polydipsia due to deficiency-heat.

[0031] Hibiscus root: astringent, neutral in nature. It has the effects of clearing heat and dampness, detoxifying and reducing swelling, cooling blood and stopping bleeding. It is often used to treat inflammation, skin diseases, and gynecological problems.

[0032] Water centipede: Pungent, slightly bitter, and sweet, with a neutral nature. It enters the lung and liver meridians. It has the effects of dispelling wind and relieving exterior symptoms, relieving coughs, detoxifying and reducing swelling, clearing heat and dampness, and promoting blood circulation and detoxification. It is used for colds, fever, headaches, acute bronchitis, exogenous coughs, whooping cough, malaria, jaundice, dysentery, erosions, sores, itchy skin, snake bites, rheumatoid arthritis, and traumatic injuries.

[0033] Wupaozi: It has a sweet and astringent taste and a cool nature. It has the effects of clearing away heat and detoxifying, cooling blood and stopping bleeding, promoting blood circulation and reducing swelling. It is often used as an auxiliary conditioning for sore throat, blood stasis and lumps, dysentery, metrorrhagia, and indigestion caused by summer heat.

[0034] The present invention uses Pueraria root as the monarch, which has the functions of relieving muscle pain, reducing fever, promoting body fluid and quenching thirst, and raising yang and stopping diarrhea. Scutellaria baicalensis clears heat and dampness, clears fire and detoxifies, assists Pueraria root in clearing lung heat and anti-inflammatory effects, and enhances antipyretic and antibacterial effects. Chinese yam strengthens the spleen and lungs, replenishes qi and nourishes yin, harmonizes the various drugs, prevents heat-clearing drugs from damaging the body, and simultaneously enhances lung and spleen functions and promotes recovery. The two are collectively ministerial drugs. Hibiscus root has the effects of clearing heat and detoxifying, promoting blood circulation and unblocking meridians, which can assist the monarch and ministerial drugs in strengthening the heat-clearing and detoxifying effects, and also helps to alleviate the lung symptoms caused by heat-toxic obstruction, thus serving as an adjuvant. Water centipede and black bubble fruit have potent anti-inflammatory, antioxidant and tissue repair effects. Water centipede has the effects of unblocking meridians and relieving pain, relieving asthma and resolving phlegm, and plays a role in guiding the various drugs to ascend to the lung meridian and enhance the distribution of drug efficacy in this prescription. It also has the effects of harmonizing the entire prescription and enhancing the effects of relieving cough and relieving asthma. The two are collectively referred to as the guiding drugs.

[0035] As can be seen from the above, the Chinese medicine for preventing and treating acute lung injury of the present invention has multiple effects such as anti-oxidation, anti-inflammatory, immunomodulation and promotion of tissue repair, and has the advantages of high efficacy and no toxic side effects. The experimental efficacy is very good. Taking Example 1 as an example, the experimental data are as follows:

[0036] 1. Establishment, grouping, and intervention of acute lung injury (ALI) mouse model

[0037] Eight-week-old male C57BL / 6 mice weighing 18–22 g were selected and randomly divided into three groups (n=6) after 7 days of adaptive feeding: a control group (BL group), a model group (LPS group), and a treatment group (LPS+QFFYT group). The LPS+QFFYT group was gavaged daily for 6 consecutive days starting on the day of modeling with the ultrafine powder suspension of Example 1 of the present invention (the dry powder prepared in Example 1 was dissolved in ultrapure water, with a weight-to-volume ratio of dry powder to ultrapure water of 1.25:1) at 500 mg / (kg / d). The control and model groups were gavaged daily with an equal volume of normal saline as a control treatment.

[0038] 2. Effects on Lung Pathological Changes and Damage in ALI Mice

[0039] Eight hours after the last dose on day 7, mice were anesthetized with an intraperitoneal injection of 1% sodium pentobarbital, and bronchoalveolar lavage fluid (BALF) and lung tissue were collected. Part of the lung tissue was fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned. The tissue was then stained with hematoxylin and eosin (HE) to observe pathomorphological changes. The remaining tissue was frozen at -80°C for subsequent molecular biology analysis.

[0040] 3. Determination of Lung Index and Lung Wet / Dry Weight Ratio (W / D)

[0041] The left or right upper lobe of the mouse lung was removed, cleaned of blood with cold saline, and dried with filter paper. The wet weight was immediately measured. The tissue was then dried in a 60°C oven for 48 hours and weighed. The wet / dry weight ratio (W / D) was calculated to assess the degree of pulmonary edema. The pulmonary index (Lung Index) = total lung weight / mouse body weight × 100% was used to indirectly reflect the level of pulmonary inflammation or edema.

[0042] 4. Detection of inflammatory factor levels in BALF by enzyme-linked immunosorbent assay (ELISA)

[0043] The collected BALF samples were centrifuged at 4°C (3000 rpm, 15 min) to remove cells and impurities, and the supernatant was collected. TNF-α, IL-1β, IL-6, and IL-8 levels in BALF were determined according to the ELISA kit instructions, and the absorbance was read at 450 nm using a microplate reader.

[0044] 5. Flow cytometry analysis of the number and phenotype of inflammatory cells in BALF

[0045] After centrifugation of BALF (3000rpm, 15min), the cell pellet was collected, and red blood cell lysis buffer was added to lyse the red blood cells. After washing twice with PBS, the cells were resuspended in 1mL PBS. After counting the total number of cells using trypan blue staining, an appropriate amount of cells was taken, and fluorescently labeled monoclonal antibodies (such as CD45, CD3, CD19, CD14, Ly6G, etc.) were added and incubated in the dark for 30min. After washing with PBS to remove unbound antibodies, the relative proportions and numbers of different types of inflammatory cells were detected and analyzed using flow cytometry. 6. Detection of SOD, MDA, and GSH content in lung tissue

[0046] An appropriate amount of lung tissue was collected and homogenized with lysis buffer (at a tissue mass to buffer volume ratio of 1:9). The mixture was then lysed on ice for 30 minutes and centrifuged at 4°C (5000 rpm for 20 minutes). The supernatant was collected. Protein concentration was determined using the BCA assay. Superoxide dismutase (SOD), malondialdehyde (MDA) content, and glutathione (GSH) levels were measured according to the respective kit instructions, and absorbance values ​​were read using a microplate reader. The regulatory effect of QFFYT on oxidative stress was evaluated by measuring and comparing superoxide dismutase (SOD) activity, malondialdehyde (MDA) content, and glutathione (GSH) levels in the lung tissues of mice in each group.

[0047] 7. Real-time fluorescence quantitative PCR (RT-qPCR) detection of inflammatory factor mRNA expression levels

[0048] The mRNA expression levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) in the lung tissues of mice were detected by RT-qPCR technology, and the expression differences among the mice groups were compared.

[0049] About 20 mg of lung tissue was taken, and total RNA was extracted using a centrifugal column animal tissue RNA extraction kit. The purity and concentration were detected by NanoDrop. After reverse transcription and synthesis of cDNA, qPCR reaction was performed using the SYBR Green method. The total reaction system was 20 μL, containing: 10 μL of SYBR mixture, 2 μL of upstream primer, 2 μL of downstream primer, 2 μL of cDNA template, and 4 μL of DEPC water. The reaction procedure was cycled 40 times according to the three-step method set in the SYBR manual, and GAPDH was used as the internal reference gene. The primer sequences used are as follows:

[0050]

[0051] 8. Western blotting to detect inflammatory pathway protein expression

[0052] Western blotting was used to detect the protein expression levels of p-NF-κB / NF-κB and p-STAT3 / STAT3 in the lung tissues of each group of mice to analyze the regulatory effect of QFFYT on the inflammatory signaling pathway.

[0053] Lung tissue samples were collected and homogenized in RIPA lysis buffer. Protein concentration was quantified using the BCA assay and denatured at 95°C for 10 minutes. Samples were separated by SDS-PAGE and transferred to a PVDF membrane. The membrane was blocked with 5% bovine serum albumin or 5% skim milk powder for 2 hours at room temperature. Antibodies against p-NF-κB, NF-κB, p-STAT3, STAT3, and a loading control were then added and incubated overnight at 4°C. The membrane was washed three times with TBST for 10 minutes, followed by the addition of an anti-rabbit HRP-conjugated secondary antibody. The membrane was incubated for 2 hours at room temperature and washed three times. Target protein bands were detected using ECL chemiluminescence reagent.

[0054] 9. Transmission electron microscopy (TEM) observation of mitochondrial ultrastructure in lung tissue

[0055] Mouse lung tissue was quickly removed and fixed overnight in pre-cooled glutaraldehyde at 4°C. The tissue was then rinsed three times (15 minutes each) and post-fixed in 1% osmium phosphate for 1–2 hours. After dehydration with graded ethanol, replacement with acetone, and embedding in epoxy resin, ultrathin sections were prepared and stained with uranyl acetate and lead citrate. Transmission electron microscopy (80–120 kV) was used to examine mitochondrial structure in the lung tissue, including changes in cristae, double membranes, volume, and integrity.

[0056] 10. Statistical Analysis

[0057] All experimental data were statistically analyzed using GraphPad Prism 9.5 software. The results are presented as mean ± standard deviation. The differences between the groups were compared using one-way ANOVA with LSD or Tukey post hoc test. P values ​​< 0.05 indicated statistical significance.

[0058] 11. Results

[0059] Effects of traditional Chinese medicine for the prevention and treatment of acute lung injury (QFFYT, Qingfei Fuyuan Decoction) on lung pathological changes and damage in ALI mice. Figure 1 The BL group showed intact alveolar tissue structure, with no exudates or inflammatory cell infiltration, and no significant pathological changes. The LPS group displayed typical ALI pathological features, including alveolar rupture, significant alveolar wall thickening, and pink exudates and inflammatory cell infiltration within the alveolar cavity. Compared with the LPS group, the LPS+QFFYT group showed significantly less lung damage and a marked decrease in inflammatory cell infiltration, demonstrating a significant improvement. This demonstrates that QFFYT can effectively alleviate LPS-induced acute lung injury and improve alveolar pathology.

[0060] The results of the experiment on the effect of QFFYT on the lung index and lung wet / dry ratio (W / D) of ALI mice are shown in Figure 2 Compared with the BL group, the lung / body weight ratio and lung wet / dry weight ratio (W / D) of mice in the LPS group were significantly increased (P<0.001), indicating successful model establishment. Compared with the LPS group, the LPS+QFFYT group significantly reduced the lung / body weight ratio (P<0.001) and lung wet / dry weight ratio (W / D) (P<0.001). This demonstrates that QFFYT significantly reduces pulmonary edema in ALI mice by reducing the lung index and lung wet / dry weight ratio, thereby alleviating organ damage.

[0061] The results of the experiment on the effect of QFFYT on TNF-α, IL-1β, IL-6 and IL-8 in the bronchoalveolar lavage fluid of ALI mice are shown in Figure 3 Compared with the BL group, the levels of TNF-α, IL-1β, IL-6, and IL-8 in the bronchoalveolar lavage fluid of the LPS group were significantly increased (P < 0.001), indicating that the model was successfully established. Compared with the LPS group, the LPS+QFFYT group significantly reduced the levels of inflammatory factors (P < 0.001). This study demonstrated that QFFYT can alleviate LPS-induced acute lung injury by significantly reducing the release of proinflammatory factors such as TNF-α, IL-1β, IL-6, and IL-8, providing experimental evidence for the clinical anti-inflammatory application of QFFYT.

[0062] The results of flow cytometric analysis of the number and phenotype of inflammatory cells in BALF are shown in Figure 4 Compared with the BL group, the total number and number of various inflammatory cells in the LPS group were significantly increased, with a significant increase in the proportion of neutrophils. Compared with the LPS group, the LPS+QFFYT group significantly reduced the total number and number of various inflammatory cells, as well as the proportion of neutrophils. This suggests that QFFYT can alleviate LPS-induced acute lung injury by inhibiting the infiltration of inflammatory cells such as macrophages and neutrophils.

[0063] The results of the effects of QFFYT on the levels of SOD, MDA, and GSH in the lung tissue of ALI mice are shown in Figure 5 In the LPS group, SOD activity was significantly decreased (P<0.001), while MDA content was significantly increased (P<0.001), indicating enhanced oxidative stress. Concomitantly, GSH levels decreased (P<0.001), indicating impairment of the antioxidant defense system. Compared with the LPS group, the LPS+QFFYT group showed a significant recovery of SOD activity (P<0.001), a decrease in MDA content (P<0.001), and an increase in GSH levels (P<0.001), suggesting improved lung function by alleviating oxidative damage. This study demonstrates that QFFYT can alleviate lung damage in ALI mice by significantly inhibiting oxidative stress and restoring the antioxidant defense system.

[0064] The results of the effects of QFFYT on the expression of TNF-α, IL-1β, IL-6, IL-8, and MCP-1 mRNA in the lung tissue of ALI mice are shown in Figure 6 Compared with the BL group, the mRNA expression levels of TNF-α, IL-1β, IL-6, IL-8, and MCP-1 in the lung tissues of mice in the LPS group were significantly increased (P<0.001). Compared with the LPS group, the LPS+QFFYT group significantly inhibited the expression of these inflammatory factors (P<0.001). This suggests that QFFYT can alleviate ALI by downregulating the expression of proinflammatory cytokines, providing experimental evidence for its clinical application.

[0065] The results of the effects of QFFYT on the expression of p-NF-κB / NF-κB and p-STAT3 / STAT3 proteins in the lung tissue of ALI mice are shown in Figure 7 Compared with the BL group, the expression levels of p-NF-κB / NF-κB and p-STAT3 / STAT3 in the lung tissues of mice in the LPS model group were significantly increased (P<0.001), indicating activation of inflammatory pathways. Compared with the LPS group, the expression levels of p-NF-κB / NF-κB (P<0.001, P=0.001) and p-STAT3 / STAT3 (P<0.001) were significantly decreased in the LPS+QFFYT group, confirming that QFFYT can alleviate inflammatory responses by inhibiting the phosphorylation of the NF-κB and STAT3 signaling pathways, providing a new strategy for the treatment of ALI.

[0066] The results of the effects of QFFYT on the mitochondrial structure changes in the lung tissue of ALI mice are shown in Figure 8 Compared with the BL group, the mitochondria in the lung tissue of mice in the LPS model group showed significant swelling, broken or absent cristae, and a significant decrease in matrix density, indicating that LPS induces severe mitochondrial damage. Compared with the LPS group, the mitochondrial structural damage was significantly reduced in the LPS+QFFYT group. This suggests that QFFYT can alleviate LPS-induced acute lung injury by maintaining mitochondrial structural integrity, and its mechanism of action may be related to improving mitochondrial dysfunction.

[0067] Each of the above experiments was repeated three times, and the results were consistent. At the same time, while performing the above experiments on Example 1, the present invention also performed the same experiments on Examples 2-5, and obtained the same or similar results as Example 1. They are not listed here one by one, which shows that the present invention has good effects and stable and reliable therapeutic effects.

[0068] As can be seen from the above, the present invention has a scientific and reasonable formulation, abundant and readily available raw materials, and a simple preparation process. Compared with the prior art, it has the following advantages:

[0069] 1. The present invention has multiple effects such as anti-oxidation, anti-inflammatory, immunomodulation and promotion of tissue repair, which can synergistically inhibit the inflammatory response and oxidative stress in the process of acute lung injury and effectively improve lung function;

[0070] 2. The present invention can effectively intervene in the occurrence and development of lung injury by regulating the NF-κB / STAT3 signaling pathway, thereby achieving a therapeutic effect;

[0071] 3. The present invention can not only prevent and treat acute lung injury, but also alleviate complications such as dyspnea and immune dysfunction caused by the injury, promote lung tissue repair, and improve the patient's recovery level;

[0072] 4. This invention utilizes a water extraction-alcohol precipitation method to extract the compound extract of QFFYT, aiming to improve the extraction efficiency and bioavailability of its active ingredients. This method effectively separates and concentrates the active ingredients from the medicinal material, enhancing their efficacy. This method preserves the natural properties of traditional Chinese medicine while ensuring the purity and stability of the extract, laying the foundation for further research into the mechanism of action of QFFYT.

[0073] 5. The present invention is based on the pharmacological potential of Radix Glehniae Rhizoma and adopts modern ultrafine grinding technology to prepare Radix Glehniae Rhizoma ultrafine powder, thereby improving the dissolution rate and bioavailability of its effective ingredients. By constructing an LPS-induced ALI mouse model, the present invention systematically evaluates its comprehensive effects and potential molecular mechanisms in inhibiting lung tissue inflammation, alleviating oxidative stress, and protecting mitochondrial structure, especially the regulatory effects on classic inflammatory signaling pathways such as NF-κB and STAT3. In summary, the present invention, through the combination of modern pharmacology and traditional Chinese medicine preparation technology, not only explores a new form of Radix Glehniae Rhizoma preparation with practical prospects, but also provides a theoretical basis and experimental basis for the application of natural medicines in inflammatory diseases such as acute lung injury. It has a high degree of application acceptance and cultural recognition, meets modern clinical needs, has clear innovation, practicality and scalability, and is expected to become an important supplement or even an alternative to existing treatment methods, with significant social and economic benefits.

Claims

1. A Chinese medicine for preventing and treating acute lung injury, characterized in that: The invention comprises the following raw materials in weight percentage: 24-26% of kudzu root, 18-22% of scutellaria baicalensis, 18-22% of yam, 14-16% of hibiscus root, 9-12% of water centipede and 9-12% of wupuzi fruit; wherein the raw materials are crushed and mixed, and water is added in a ratio of 1:10 of the total weight of the raw materials to the volume, and the temperature is kept at 80-90°C after boiling for 2 hours, and the decoction is filtered, and the residue is removed to obtain the original juice, and the original juice is concentrated to a concentrated liquid with a volume ratio of 1:2 of the total weight of the raw materials to obtain the concentrated liquid, and 70% ethanol twice the volume of the concentrated liquid is added to the concentrated liquid, and the mixture is stirred evenly and allowed to settle for 24 hours, and the precipitate is filtered, and the supernatant of the concentrated liquid is pre-frozen at -40°C, and then sublimated and dried at -30°C under a vacuum condition of ≤10 Pa, and then at 30 ℃ and decompose and dry until a dry powder extract of traditional Chinese medicine with a water content of less than 3% is obtained; the weight-to-volume ratio is measured in g for solid and ml for liquid.

2. The Chinese medicine for preventing and treating acute lung injury according to claim 1, characterized in that The invention comprises the following raw materials in percentage by weight: 25% of kudzu root, 20% of scutellaria baicalensis, 20% of yam, 15% of hibiscus root, 10% of water centipede and 10% of black bubble fruit.

3. The Chinese medicine for preventing and treating acute lung injury according to claim 1, characterized in that The invention comprises the following raw materials in percentage by weight: 24% of kudzu root, 22% of scutellaria baicalensis, 18% of yam, 15% of hibiscus root, 12% of water centipede and 9% of black bubble fruit.

4. The Chinese medicine for preventing and treating acute lung injury according to claim 1, characterized in that The invention comprises the following raw materials in percentage by weight: 26% of kudzu root, 18% of scutellaria baicalensis, 21% of yam, 14% of hibiscus root, 9% of water centipede and 12% of black bubble fruit.

5. The Chinese medicine for preventing and treating acute lung injury according to claim 1, characterized in that The invention comprises the following raw materials in percentage by weight: 26% of kudzu root, 19% of scutellaria baicalensis, 21% of yam, 14% of hibiscus root, 11% of water centipede and 9% of black bubble fruit.

6. The Chinese medicine for preventing and treating acute lung injury according to claim 1, characterized in that The invention comprises the following raw materials in percentage by weight: 25% of kudzu root, 21% of scutellaria baicalensis, 19% of yam, 14% of hibiscus root, 10% of water centipede and 11% of black bubble fruit.

Images